Nifty
Sensex
:
:
15763.05
52586.84
-15.40 (-0.10%)
-66.23 (-0.13%)

Pharmaceuticals & Drugs

Rating :
59/99

BSE: 526953 | NSE: VENUSREM

467.60
30-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  463.00
  •  467.60
  •  453.50
  •  445.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  64836
  •  301.68
  •  477.25
  •  73.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 623.97
  • 10.10
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 842.30
  • N/A
  • 1.51

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 40.81%
  • 2.40%
  • 51.34%
  • FII
  • DII
  • Others
  • 0.04%
  • 0.00%
  • 5.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.61
  • -3.98
  • -2.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -7.61
  • -12.84
  • 0.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -31.19

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.40
  • 6.84
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.37
  • 0.31
  • 0.35

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.25
  • 7.30
  • 8.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
111.37
83.06
34.08%
121.94
96.86
25.89%
126.07
87.89
43.44%
188.75
73.65
156.28%
Expenses
106.88
75.53
41.51%
103.86
86.06
20.68%
115.42
75.19
53.50%
173.19
63.86
171.20%
EBITDA
4.50
7.53
-40.24%
18.08
10.79
67.56%
10.65
12.71
-16.21%
15.55
9.78
59.00%
EBIDTM
4.04%
9.07%
14.83%
11.14%
8.45%
14.46%
8.24%
13.28%
Other Income
3.49
1.37
154.74%
1.83
1.77
3.39%
12.28
1.35
809.63%
2.04
0.82
148.78%
Interest
0.96
-1.82
-
1.81
4.07
-55.53%
7.39
4.91
50.51%
2.85
6.18
-53.88%
Depreciation
9.38
6.47
44.98%
8.70
8.48
2.59%
8.61
8.56
0.58%
3.59
8.50
-57.76%
PBT
18.20
-4.56
-
13.86
0.02
69,200.00%
14.52
0.58
2,403.45%
1.97
-4.07
-
Tax
-16.91
0.82
-
2.21
0.99
123.23%
1.49
0.16
831.25%
0.00
0.00
0
PAT
35.11
-5.38
-
11.65
-0.96
-
13.03
0.42
3,002.38%
1.97
-4.07
-
PATM
31.53%
-6.48%
9.56%
-0.99%
10.33%
0.47%
1.05%
-5.53%
EPS
28.45
-4.36
-
9.44
-0.78
-
10.55
0.34
3,002.94%
1.60
-3.30
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
548.13
341.46
321.89
372.41
400.04
418.27
463.99
541.56
468.64
409.84
363.09
Net Sales Growth
60.53%
6.08%
-13.57%
-6.91%
-4.36%
-9.85%
-14.32%
15.56%
14.35%
12.88%
 
Cost Of Goods Sold
340.60
174.31
181.95
205.08
227.07
238.51
268.94
300.00
262.26
225.91
201.50
Gross Profit
207.53
167.15
139.94
167.33
172.97
179.77
195.05
241.55
206.38
183.92
161.59
GP Margin
37.86%
48.95%
43.47%
44.93%
43.24%
42.98%
42.04%
44.60%
44.04%
44.88%
44.50%
Total Expenditure
499.35
300.64
289.37
332.94
349.32
337.11
374.81
403.33
348.53
306.96
273.00
Power & Fuel Cost
-
4.73
4.86
4.29
4.14
4.01
3.80
3.38
3.05
2.71
2.72
% Of Sales
-
1.39%
1.51%
1.15%
1.03%
0.96%
0.82%
0.62%
0.65%
0.66%
0.75%
Employee Cost
-
46.02
42.10
39.31
34.27
32.44
32.36
30.45
27.30
24.83
20.38
% Of Sales
-
13.48%
13.08%
10.56%
8.57%
7.76%
6.97%
5.62%
5.83%
6.06%
5.61%
Manufacturing Exp.
-
20.84
21.01
36.10
42.48
15.70
17.29
22.10
20.61
18.18
17.05
% Of Sales
-
6.10%
6.53%
9.69%
10.62%
3.75%
3.73%
4.08%
4.40%
4.44%
4.70%
General & Admin Exp.
-
17.57
11.85
13.52
13.26
11.97
15.67
14.74
11.82
12.14
11.54
% Of Sales
-
5.15%
3.68%
3.63%
3.31%
2.86%
3.38%
2.72%
2.52%
2.96%
3.18%
Selling & Distn. Exp.
-
37.18
27.60
34.65
28.10
34.48
36.75
32.65
23.50
22.98
19.82
% Of Sales
-
10.89%
8.57%
9.30%
7.02%
8.24%
7.92%
6.03%
5.01%
5.61%
5.46%
Miscellaneous Exp.
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
19.82
% Of Sales
-
0%
0%
0%
0%
0%
0%
0%
0%
0.05%
0%
EBITDA
48.78
40.82
32.52
39.47
50.72
81.16
89.18
138.23
120.11
102.88
90.09
EBITDA Margin
8.90%
11.95%
10.10%
10.60%
12.68%
19.40%
19.22%
25.52%
25.63%
25.10%
24.81%
Other Income
19.64
5.31
6.09
2.39
4.28
2.01
0.68
0.47
0.44
0.49
0.40
Interest
13.01
13.34
25.41
35.56
36.38
37.98
41.21
29.40
24.63
27.49
18.86
Depreciation
30.28
32.01
33.98
33.83
40.26
41.68
46.00
40.22
33.08
25.02
18.98
PBT
48.55
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
50.85
52.63
Tax
-13.21
1.96
-1.15
3.16
-4.56
1.81
-2.51
4.78
5.53
3.78
6.41
Tax Rate
-27.21%
-24.41%
3.87%
-11.48%
21.07%
51.57%
-94.72%
6.92%
8.80%
7.43%
12.18%
PAT
61.76
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
47.08
46.22
PAT before Minority Interest
61.76
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
57.31
47.08
46.22
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
11.27%
-2.93%
-8.88%
-8.24%
-4.27%
0.41%
1.11%
11.87%
12.23%
11.49%
12.73%
PAT Growth
718.22%
-
-
-
-
-67.05%
-91.98%
12.20%
21.73%
1.86%
 
EPS
46.09
-7.46
-21.32
-22.90
-12.75
1.27
3.85
47.99
42.77
35.13
34.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
323.37
332.52
361.91
388.67
437.62
456.68
461.61
379.13
307.29
236.92
Share Capital
12.34
12.34
12.34
12.34
11.44
11.44
11.44
10.54
9.74
9.13
Total Reserves
311.03
320.18
349.57
376.33
426.18
445.24
450.17
363.81
288.53
223.59
Non-Current Liabilities
95.82
136.68
158.47
179.52
212.05
221.55
161.75
147.18
113.51
99.41
Secured Loans
24.19
61.29
86.60
112.69
134.57
150.95
114.76
103.89
75.45
65.97
Unsecured Loans
47.87
54.73
50.84
49.13
56.47
51.34
25.22
25.22
23.68
22.02
Long Term Provisions
6.63
5.32
4.50
4.29
3.79
3.78
3.31
2.91
2.50
1.94
Current Liabilities
218.53
263.62
230.38
196.81
193.14
162.83
210.99
191.25
153.22
124.53
Trade Payables
36.70
36.00
29.33
29.73
25.14
29.56
31.22
18.76
12.55
7.02
Other Current Liabilities
95.65
110.30
78.47
46.16
42.71
15.96
54.70
58.18
43.44
40.07
Short Term Borrowings
85.58
112.80
121.26
119.16
123.32
115.40
110.08
95.68
83.24
63.17
Short Term Provisions
0.61
4.52
1.32
1.76
1.97
1.91
14.99
18.63
13.99
14.27
Total Liabilities
637.72
732.82
750.76
765.00
842.81
841.06
834.35
717.56
574.02
460.86
Net Block
289.37
364.45
389.20
406.18
452.48
443.65
439.46
401.42
355.39
293.28
Gross Block
623.96
707.02
702.77
686.50
679.57
641.12
587.38
511.00
430.25
343.15
Accumulated Depreciation
334.59
342.57
313.57
280.32
227.09
197.47
147.93
109.58
74.87
49.86
Non Current Assets
349.77
467.39
490.50
505.60
565.75
607.85
562.24
491.97
404.40
322.49
Capital Work in Progress
24.63
64.76
64.76
66.25
80.37
78.30
67.80
47.81
23.00
15.31
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
35.77
38.18
36.53
33.17
32.90
85.91
54.98
42.74
26.01
13.91
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
287.95
265.43
260.27
259.41
277.07
233.21
272.11
225.58
169.63
138.37
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
141.12
142.73
138.17
140.60
143.29
142.87
142.26
128.03
96.82
75.43
Sundry Debtors
30.69
38.04
47.27
47.29
61.59
63.22
64.99
47.11
40.10
35.74
Cash & Bank
2.13
2.81
3.98
3.56
7.07
3.62
4.41
6.36
2.95
3.12
Other Current Assets
114.01
5.15
4.84
0.00
65.12
23.51
60.47
44.08
29.77
24.07
Short Term Loans & Adv.
58.29
76.70
66.00
67.96
65.12
23.51
60.47
44.08
29.77
23.87
Net Current Assets
69.43
1.81
29.88
62.59
83.93
70.38
61.12
34.33
16.41
13.84
Total Assets
637.72
732.82
750.77
765.01
842.82
841.06
834.35
717.55
574.03
460.86

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
77.01
45.33
31.19
58.93
46.88
67.80
52.65
52.15
41.67
37.35
PBT
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
62.84
50.85
52.63
Adjustment
41.56
60.72
66.24
70.61
56.41
83.56
37.21
40.72
29.96
24.74
Changes in Working Capital
20.23
5.37
-7.52
9.96
-13.04
-18.40
-53.65
-51.41
-39.14
-40.02
Cash after chg. in Working capital
62.57
45.33
31.19
58.93
46.88
67.80
52.65
52.15
41.67
37.35
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
14.44
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4.75
-11.33
-11.48
-18.32
2.92
-67.18
-94.66
-103.89
-95.15
-96.43
Net Fixed Assets
124.42
-5.05
-11.74
18.95
-50.18
-67.39
-93.77
-101.63
-93.38
-94.69
Net Investments
0.00
0.00
28.60
0.00
0.00
0.00
0.00
0.00
-0.37
-3.58
Others
-129.17
-6.28
-28.34
-37.27
53.10
0.21
-0.89
-2.26
-1.40
1.84
Cash from Financing Activity
-73.00
-35.17
-39.23
-44.13
-46.35
-1.42
40.06
55.15
53.31
59.80
Net Cash Inflow / Outflow
-0.74
-1.17
-19.52
-3.51
3.46
-0.79
-1.95
3.41
-0.17
0.72
Opening Cash & Equivalents
2.81
3.98
0.00
7.07
3.62
4.41
6.36
2.95
3.12
2.40
Closing Cash & Equivalent
2.13
2.81
-19.52
3.56
7.07
3.62
4.41
6.36
2.95
3.12

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
262.01
269.42
293.23
314.92
382.47
399.13
403.43
355.10
306.18
254.92
ROA
-1.46%
-3.85%
-4.05%
-2.12%
0.20%
0.62%
8.29%
8.87%
9.10%
11.40%
ROE
-3.05%
-8.23%
-8.18%
-4.13%
0.38%
1.12%
15.38%
17.04%
17.73%
23.07%
ROCE
0.90%
-0.67%
1.17%
2.00%
5.35%
5.74%
14.06%
14.85%
16.47%
19.24%
Fixed Asset Turnover
0.51
0.46
0.54
0.59
0.63
0.76
0.99
1.00
1.06
1.20
Receivable days
36.73
48.37
46.34
49.67
54.45
50.42
37.72
33.88
33.71
32.14
Inventory Days
151.71
159.26
136.61
129.51
124.86
112.15
90.94
87.34
76.56
68.94
Payable days
42.53
37.91
30.30
26.74
26.74
27.25
21.28
15.09
11.03
8.63
Cash Conversion Cycle
145.91
169.72
152.65
152.44
152.57
135.32
107.37
106.14
99.25
92.44
Total Debt/Equity
0.68
0.90
0.85
0.80
0.77
0.70
0.63
0.72
0.74
0.80
Interest Cover
0.40
-0.17
0.23
0.41
1.09
1.06
3.35
3.55
2.85
3.79

News Update:


  • Venus Remedies launches full-fledged Consumer Healthcare division
    15th Jul 2021, 16:35 PM

    The newly launched business division would introduce disruptive products in these segments in India over the next five years

    Read More
  • Venus Remedies unveils covid protection policy
    12th Jul 2021, 13:14 PM

    The company will pay an amount equivalent to one month of gross salary for the next 12 months to the nominated dependents of permanent employees in case of their untimely demise due to Covid-19

    Read More
  • Venus Remedies wins legal battle against French firm for paracetamol patent
    18th Jun 2021, 13:25 PM

    The Indian drug firm had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.